European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
The European Commission (EC) has granted marketing authorization for BioNTechs/Pfizers 2026-2027 COVID-19 vaccine formula targeting the XFG variant.
The European Commission (EC) has granted marketing authorization for BioNTechs/Pfizers 2026-2027 COVID-19 vaccine formula targeting the XFG variant.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.